Original Research J Clin Psychiatry April 2025

Improvements Over Time with Valbenazine in Elderly Adults (≥65 Years) with Tardive Dyskinesia: Post Hoc Analyses of 2 Long-Term Studies

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary Older adults exposed to antipsychotics and other dopamine receptor blocking agents are at especially high risk for tardive dyskinesia, yet treatment data in patients aged 65 years and older have been limited. These analyses address a common clinical dilemma: whether long-term valbenazine provides meaningful TD improvement in elderly patients without destabilizing psychiatric status or adding new safety concerns. FAQ How much did tardive dyskinesia improve with valbenazine in adults aged 65 years and older? 11 questions
Key Takeaways In adults aged ≥65 years, AIMS improvement exceeded the estimated minimal clinically important difference of −2 points by Week 8 and continued to deepen over time, with mean changes of −4.5 ± 0.7 at Week 8, −8.6 ± 0.9 at Week 24, and −8.8 ± 0.9 at Week 48. 6 takeaways Clinical Guide How should clinicians initiate, assess, and monitor valbenazine treatment in adults aged 65 years and older with tardive dyskinesia? 10 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Live Webinar
and Q&A With
Dr Deligiannidis

JULY 16 · REGISTER NOW
Webinar ad featuring Dr. Kristina M. Deligiannidis on PPD treatment options

Subscribe to read
more articles

Subscribe